GILEAD SCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
GILEAD SCIENCES, INC. (GILD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements · last filed 2014-02-25
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2012-12-31 was $0.00.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2012-09-30 was -$42.25M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2012-06-30 was -$5.53M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2012-03-31 was -$16.52M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2013 was $0.00.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2012 was -$64.23M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2011 was -$38.43M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2010 was -$40.03M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$42.25M derived: sum of 2 quarters · filed 2014-02-25 | -$47.79M derived: sum of 3 quarters · filed 2014-02-25 | -$64.23M 10-K · filed 2014-02-25 |
| 2012-09-30 | -$42.25M 10-Q · filed 2012-11-06 | -$47.79M derived: sum of 2 quarters · filed 2012-11-06 | -$64.23M 10-Q · filed 2012-11-06 | -$74.11M derived: sum of 4 quarters · filed 2013-02-27 |
| 2012-06-30 | -$5.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$22.06M 10-Q · filed 2012-08-01 | -$31.86M derived: sum of 3 quarters · filed 2013-02-27 | -$33.21M derived: sum of 4 quarters · filed 2013-02-27 |
| 2012-03-31 | -$16.52M 10-Q · filed 2012-05-04 | -$26.32M derived: sum of 2 quarters · filed 2013-02-27 | -$27.67M derived: sum of 3 quarters · filed 2013-02-27 | -$34.12M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-12-31 | -$9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$11.15M derived: sum of 2 quarters · filed 2013-02-27 | -$17.60M derived: sum of 3 quarters · filed 2013-02-27 | -$38.43M 10-K · filed 2013-02-27 |
| 2011-09-30 | -$1.35M 10-Q · filed 2012-11-06 | -$7.80M derived: sum of 2 quarters · filed 2012-11-06 | -$28.63M 10-Q · filed 2012-11-06 | -$47.13M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-06-30 | -$6.45M 10-Q · filed 2012-08-01 | -$27.28M 10-Q · filed 2012-08-01 | -$45.78M derived: sum of 3 quarters · filed 2012-08-01 | -$53.83M derived: sum of 4 quarters · filed 2012-08-01 |
| 2011-03-31 | -$20.83M 10-Q · filed 2012-05-04 | -$39.33M derived: sum of 2 quarters · filed 2012-05-04 | -$47.38M derived: sum of 3 quarters · filed 2012-05-04 | -$59.93M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | -$18.50M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$26.55M derived: sum of 2 quarters · filed 2012-02-23 | -$39.10M derived: sum of 3 quarters · filed 2012-02-23 | -$40.03M 10-K · filed 2012-02-23 |
| 2010-09-30 | -$8.05M 10-Q · filed 2011-11-04 | -$20.60M derived: sum of 2 quarters · filed 2011-11-04 | -$21.53M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | -$12.55M 10-Q · filed 2011-08-05 | -$13.48M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | -$935.00K 10-Q · filed 2011-05-09 | |||
| 2009-06-30 | -$2.97M 10-Q · filed 2010-08-09 | -$5.47M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |